These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34773142)

  • 1. Cognitive function and oral health in relapsing-remitting multiple sclerosis.
    Manchery N; Henry JD; Swayne A; Beer R; Blum S; Nangle MR
    Clin Oral Investig; 2022 Mar; 26(3):2899-2907. PubMed ID: 34773142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral health-related quality of life is more strongly correlated with mental health than with oral health in relapsing-remitting multiple sclerosis.
    Nangle MR; Manchery N; Swayne A; Boocock H; Blum S; Henry JD
    J Oral Rehabil; 2023 Jan; 50(1):62-68. PubMed ID: 36301199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive impairment differs between primary progressive and relapsing-remitting MS.
    Ruet A; Deloire M; Charré-Morin J; Hamel D; Brochet B
    Neurology; 2013 Apr; 80(16):1501-8. PubMed ID: 23516324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormalcortical thickness in relapsing-remitting multiple sclerosis, correlations with cognition impairment, and effect of modified Bushenyisui decoction on cognitive function of multiple sclerosis.
    Zhao X; Yang T; Cheng F; Yang S; Zhu W; Li S; Fan Y
    J Tradit Chin Med; 2021 Apr; 41(2):316-325. PubMed ID: 33825413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.
    Kern KC; Gold SM; Lee B; Montag M; Horsfall J; O'Connor MF; Sicotte NL
    Neuroimage Clin; 2015; 8():440-7. PubMed ID: 26106524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropsychological characteristics of benign multiple sclerosis patients: A two-year matched cohort study.
    Hegedüs K; Kárpáti J; Iljicsov A; Simó M
    Mult Scler Relat Disord; 2019 Oct; 35():150-155. PubMed ID: 31376686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting Neuropsychological Impairment in Relapsing Remitting Multiple Sclerosis: The Role of Clinical Measures, Treatment, and Neuropsychiatry Symptoms.
    Lozano-Soto E; Cruz-López ÁJ; Gutiérrez R; González M; Sanmartino F; Rashid-Lopez R; Espinosa-Rosso R; Forero L; González-Rosa JJ
    Arch Clin Neuropsychol; 2021 May; 36(4):475-484. PubMed ID: 33067616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measures of Thalamic Integrity are Associated with Cognitive Functioning in Fingolimod-treated Multiple Sclerosis Patients.
    Conway DS; Planchon SM; Oh SH; Nakamura K; Thompson NR; Sakaie K; Ontaneda D
    Mult Scler Relat Disord; 2021 Jan; 47():102635. PubMed ID: 33260053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different cognitive profiles of Brazilian patients with relapsing-remitting and primary progressive multiple sclerosis.
    Rodrigues DN; Paes RA; Vasconcelos CC; Landeira-Fernandez J; Alvarenga MP
    Arq Neuropsiquiatr; 2011 Aug; 69(4):590-5. PubMed ID: 21877025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between cognitive and clinical disability across MS subtypes: The role of the underlying brain damage.
    Gois LCP; Pimentel-Silva LR; Damasceno BP; Damasceno A
    Mult Scler Relat Disord; 2021 Feb; 48():102701. PubMed ID: 33477004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional and structural connectivity substrates of cognitive performance in relapsing remitting multiple sclerosis with mild disability.
    Has Silemek AC; Fischer L; Pöttgen J; Penner IK; Engel AK; Heesen C; Gold SM; Stellmann JP
    Neuroimage Clin; 2020; 25():102177. PubMed ID: 32014828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of the INECO frontal screening (IFS) in the detection of executive dysfunction in patients with relapsing-remitting multiple sclerosis (RRMS).
    Bruno D; Torralva T; Marenco V; Ardilla JT; Baez S; Gleichgerrcht E; Sinay V; Roca M
    Neurol Sci; 2015 Nov; 36(11):2035-41. PubMed ID: 26113256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive functions and disability progression in relapsing-remitting multiple sclerosis: A longitudinal study.
    Heled E; Aloni R; Achiron A
    Appl Neuropsychol Adult; 2021; 28(2):210-219. PubMed ID: 31204507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theory of mind and empathy in patients at an early stage of relapsing remitting multiple sclerosis.
    Kraemer M; Herold M; Uekermann J; Kis B; Wiltfang J; Daum I; Dziobek I; Berlit P; Diehl RR; Abdel-Hamid M
    Clin Neurol Neurosurg; 2013 Jul; 115(7):1016-22. PubMed ID: 23199520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability.
    Migliore S; Ghazaryan A; Simonelli I; Pasqualetti P; Squitieri F; Curcio G; Landi D; Palmieri MG; Moffa F; Filippi MM; Vernieri F
    Behav Neurol; 2017; 2017():7404289. PubMed ID: 28912625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olfactory Dysfunction and Cognition in Radiologically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis.
    Arici Duz O; Saatci O; Karakulak EZ; Birday E; Hanoglu L
    Eur Neurol; 2021; 84(3):175-182. PubMed ID: 33831865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional reduction in cortical blood flow among cognitively impaired adults with relapsing-remitting multiple sclerosis patients.
    Hojjat SP; Cantrell CG; Vitorino R; Feinstein A; Shirzadi Z; MacIntosh BJ; Crane DE; Zhang L; Morrow SA; Lee L; O'Connor P; Carroll TJ; Aviv RI
    Mult Scler; 2016 Oct; 22(11):1421-1428. PubMed ID: 26754799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis.
    Prakash RS; Snook EM; Lewis JM; Motl RW; Kramer AF
    Mult Scler; 2008 Nov; 14(9):1250-61. PubMed ID: 18701571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of the Diagnosis of Executive Functions in Patients with Relapsing-Remitting Multiple Sclerosis.
    Borkowska AR; Daniluk B; Adamczyk K
    Int J Environ Res Public Health; 2021 Oct; 18(19):. PubMed ID: 34639827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study.
    Sundgren M; Piehl F; Wahlin Å; Brismar T
    Mult Scler Relat Disord; 2016 Nov; 10():36-43. PubMed ID: 27919496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.